Sandoz Wants the Rest of Systemix
Executive Summary
Do biotech's investors win when a large drug company buys a majority share as opposed to the whole banana? Not usually. Here we've charted the share prices at which acquirors bought shares in their majority owned affiliates, Sandoz's unsolicited bidto buy the rest of SyStemix for $17 a share represents an enormous let-down for investors.